Nebivolol Glenmark (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebivolol Glenmark, is a beta blocker presented as a tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Nebivolol Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol Glenmark is indicated for the management of high‑blood‑pressure disorders.

- Hypertension: lowers systolic and diastolic blood pressure in adults with essential hypertension. - Isolated systolic hypertension: provides effective blood‑pressure control in patients with elevated systolic readings. - High‑risk cardiovascular patients: contributes to reduction of cardiovascular risk when used as part of antihypertensive therapy.

Nebivolol Glenmark may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness: especially on standing. - Fatigue: general tiredness. - Nasal congestion: mild blockage of nasal passages. - Diarrhea: loose stools. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure. - Acute heart failure: worsening of cardiac function. - Bronchospasm: narrowing of airways, particularly in asthmatic patients. - Allergic reactions: rash, itching, or swelling. - Liver enzyme elevation: abnormal liver function tests.

Before initiating therapy, consider the following precautions.

- Cardiovascular disease: assess for heart block or severe heart failure. - Diabetes: monitor blood glucose as beta‑blockade may mask hypoglycaemia symptoms. - Renal impairment: adjust dosing in patients with reduced kidney function. - Concomitant medications: review for drugs that also lower heart rate or blood pressure. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Nebivolol Glenmark can interact with several medicines.

Major Interactions (Avoid): - Combined β‑blockers: may cause excessive bradycardia or hypotension. - Calcium channel blockers (verapamil, diltiazem): increase nebivolol plasma levels. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol exposure.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effect. - Antidiabetic agents: monitor glucose as symptoms of hypoglycaemia may be masked. - NSAIDs: can reduce antihypertensive efficacy. - Antidepressants (tricyclics): may enhance cardiac conduction effects.